A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients

NANot yet recruitingINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

May 1, 2028

Study Completion Date

November 30, 2028

Conditions
Keratoconus
Interventions
DRUG

Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light

A wavelength of 365 nm ultraviolet A light will be used to direct 5.4 J/cm2 using a beam diameter of 9.5mm to treat the de-epithelialized corneal surface of a donor cornea for 30 minutes. Every 2 minutes, the UV light will be used while another drop of riboflavin is applied on top of the donor cornea.

DRUG

Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light

The corneal tissue for the control arm will be treated the same as the crosslinked tissue except that it will not be exposed to ultraviolet light. The donor cornea will be placed on an artificial anterior chamber maintainer and the epithelium will be removed mechanically. Riboflavin solution (0.1% riboflavin and 20% dextran supplied in a sterile, single-dose container) will be applied to the cornea every 2 minutes for 30 minutes.

Trial Locations (1)

02114

Massachusetts Eye and Ear Infirmary, Boston

All Listed Sponsors
lead

Joseph B. Ciolino, MD

OTHER

NCT04584125 - A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients | Biotech Hunter | Biotech Hunter